Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Ventana Launches VENTANA Gram Staining Kit

Published: Monday, October 28, 2013
Last Updated: Sunday, October 27, 2013
Bookmark and Share
Fully automated Gram stain on the benchmark special stains platform.

Ventana Medical Systems, Inc. (Ventana) has announced the global launch of the VENTANA Gram Staining Kit. Automated for use on the VENTANA BenchMark Special Stains instrument, the Gram Staining Kit aids pathologists in the most basic classification of bacteria into Gram-positive and Gram-negative bacteria in fixed tissue samples.

Gram stain classification is clinically useful as it provides an initial indication of the nature of a patient's infection.

The Gram stain is part of a family of histochemical special stains that many laboratories around the world still run manually.

In automating the stain, Ventana gives its customers an efficient and automated method to perform this technically challenging assay, enabling them to achieve increased productivity, consistency, and testing quality.

"Tissue diagnostics play a critical role in enabling accurate diagnosis and treatment decisions for cancer patients. Ventana is dedicated to providing laboratories, pathologists and their patients with novel assays, and we are empowering our customers to achieve greater efficiencies by automating common, yet labor-intensive tests like the Gram stain," says Mara G. Aspinall, President, Ventana Medical Systems, Inc.

The Gram Staining kit is the newest addition to the Ventana product offerings on the highly successful, fully automated BenchMark Special Stains platform launched in mid-2012.

The kit offers two counterstain options and testing protocol flexibility to meet pathologists' individual preferences.

"The new Gram Staining Kit will provide our customers visual consistency and clarity rarely achieved with manual Gram staining protocols. Our commitment to quality and advancing diagnostic consistency through world-class automation shines with this new product," says Adrian Ralph, Vice President, Primary Staining, Ventana Medical Systems, Inc.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ventana Enters into Agreement with Merck KGaA
Agreement to develop companion diagnostic test for cancer treatment.
Saturday, July 12, 2014
Ventana Unveils the Latest in Digital Pathology and Lab Workflow Solutions at IAP 2012 in Cape Town
Latest versions of Virtuoso digital pathology image and workflow management software and VANTAGE workflow solution for histology lab specimen tracking to be featured
Wednesday, September 26, 2012
Appropriate and Targeted Therapy: A Significant Step Towards Personalized Medicine?
Ventana Medical Systems, Inc., has entered a strategic collaboration agreement with Bayer Pharma AG to develop a molecular companion diagnostic test.
Tuesday, January 17, 2012
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Gene Therapy Going Global with Portable Device
Portable 'gene therapy in a box' could make future cancer and HIV cures affordable in developing countries.
Preventing "Friendly Fire" in the Pancreas
Researchers inhibit process that leads to the body attacking its own insulin-producing cells.
3D-Printed Heart-On-A-Chip with Integrated Sensors
Researchers have created the first 3D-printed organ-on-a-chip with integrated sensors, paving the way for more complex, customizable devices.
Wrapping up the Genome
Researchers successfully package complete yeast genome using purified components, yielding new insights into genome mechanisms.
Drug Target for Triple-Negative Breast Cancer Found
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer.
Precision Medicine Guiding Cancer Patients’ Chemotherapy Decision
New study finds doctors use genetic test to measure breast cancer recurrence risk, make tailored treatment recommendations.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos